BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

Canbridge raised $98 million in a series D round to build out its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge also intends to solidify its rare disease...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Apr 27, 2018
Clinical News

CFDA approves Canbridge's oral mucositis drug

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved Caphosol (CAN002) to treat oral mucositis. The company has Chinese rights to the supersaturated calcium phosphate rinse from EUSA Pharma Ltd. (Hemel Hempstead, U.K.). The...
BC Extra | Apr 26, 2018
Company News

CFDA approves Canbridge's oral mucositis drug

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved Caphosol (CAN002) to treat oral mucositis. The company has Chinese rights to the supersaturated calcium phosphate rinse from EUSA Pharma Ltd. (Hemel Hempstead, U.K.). The...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BC Week In Review | Apr 13, 2015
Company News

EUSA Pharma, Jazz Pharmaceuticals deal

Essex Bidco Ltd. acquired five approved specialty hospital products and related commercial infrastructure from Jazz for about $33 million in cash. Jazz gained rights to the products under its 2012 acquisition of EUSA Pharma Inc....
BioCentury | Dec 8, 2014
Finance

Fast funding for Chinese healthcare innovators

TF Capital plans to invest its inaugural China-focused VC fund in innovation and technology in that nation's healthcare space. The firm, which has about $50 million to invest, has already made about eight investments, including...
BC Extra | Dec 3, 2014
Financial News

Canbridge raises $10M in series A

Canbridge Life Sciences Ltd. (Beijing, China) raised $10 million in a series A round from Qiming Venture Partners and TF Capital. Canbridge in-licenses compounds from small biotechs in the U.S. and Europe to develop in...
BioCentury | May 7, 2012
Strategy

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
BC Week In Review | Apr 30, 2012
Company News

EUSA, Jazz Pharmaceuticals deal

Jazz will acquire cancer-focused specialty pharma EUSA for $650 million in cash, plus a potential $50 million payment tied to 2013 U.S. sales of EUSA's Erwinaze . Jazz, which had 2011 revenue of $272.3 million, expects...
Items per page:
1 - 10 of 16